Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk

被引：1
|
作者：
Spratt, Daniel E. [1 ]
Schaeffer, Edward M. [2 ]
机构：
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Urol, 300 E Super, Chicago, IL 60611 USA
来源：
EUROPEAN UROLOGY | 2018年 / 74卷 / 04期
关键词：
CLASSIFICATION; METASTASIS; RADIATION; MORTALITY;
D O I：
10.1016/j.eururo.2018.06.001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：453 / 454
页数：2
相关论文
共 50 条
  • [1] The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer
    Braun, Avery E.
    Chan, June M.
    Neuhaus, John
    Cowan, Janet E.
    Kenfield, Stacey A.
    Van Blarigan, Erin L.
    Tenggara, Imelda
    Broering, Jeanette M.
    Simko, Jeffry P.
    Carroll, Peter R.
    Cooperberg, Matthew R.
    CANCER, 2024, 130 (10) : 1766 - 1772
  • [2] Thoughts on Criteria for Active Surveillance of Favorable-risk Prostate Cancer
    Gettman, Matthew T.
    EUROPEAN UROLOGY, 2016, 70 (06) : 961 - 962
  • [3] Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review
    Lawrentschuk, Nathan
    Klotz, Laurence
    KOREAN JOURNAL OF UROLOGY, 2010, 51 (10) : 665 - 670
  • [4] Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk
    Spratt, Daniel Eidelberg
    Zhang, Jingbin
    Santiago-Jimenez, Maria
    Davis, John W.
    Den, Robert Benjamin
    Dicker, Adam
    Kane, Christopher J.
    Pollack, Alan
    Ross, Ashley
    du Plessis, Marguerite
    Choeurng, Voleak
    Yousefi, Kasra
    Haddad, Zaid
    Davicioni, Elai
    Weinmann, Sheila
    Schaeffer, Edward M.
    Klein, Eric A.
    Karnes, R. Jeffrey
    Feng, Felix Yi-Chung
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] UNDERSTANDING POPULATION-WIDE GENOMIC RISK DISTRIBUTION AND INTEGRATING CLINICAL-GENOMIC RISK FOR PROGNOSTICATION IN PROSTATE CANCER
    Singhal, Udit
    Jiang, Ralph
    Schipper, Matthew
    Proudfoot, James
    Chase, Elisabeth
    Suresh, Krithika
    Davicioni, Elai
    Jackson, William C.
    Spratt, Daniel E.
    Dess, Robert T.
    Morgan, Todd M.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E893 - E893
  • [6] Development and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk
    Spratt, D. E.
    Dess, R. T.
    Zhang, J.
    Santiago-Jimenez, M.
    Davis, J. W.
    Den, R. B.
    Dicker, A. P.
    Kane, C. J.
    Pollack, A.
    Ross, A. E.
    du Plessis, M.
    Choeurng, V.
    Haddad, Z.
    Davicioni, E.
    Weinmann, S.
    Schaeffer, E. M.
    Klein, E. A.
    Karnes, R. J.
    Feng, F. Y.
    Nguyen, P. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S97 - S97
  • [7] OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer.
    Grimberg, Dominic C.
    Nyame, Yaw A.
    Greene, Daniel J.
    Gupta, Karishma
    Berglund, Ryan Kent
    Gong, Michael C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Klotz, Laurence
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (12): : 692 - 698
  • [9] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Laurence Klotz
    Nature Clinical Practice Oncology, 2007, 4 : 692 - 698
  • [10] Expectant management with selective delayed intervention for favorable-risk prostate cancer
    Klotz, L
    PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE, 2003, : 274 - 279
12345